AMS05: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- Study HIC#:2000034445
- Last Updated:08/07/2024
Newly diagnosed with MS?
Most people with MS start immune suppressing medications immediately after their diagnosis and remain on these medications indefinitely. However, emerging data suggests that at least some patients may not require lifelong immune suppression to control their MS.
The AMS05 clinical trial is testing the highly effective MS medication, ocrelizumab, in people with early relapsing MS, to see if a short-term treatment can lead to lasting remission. The study will provide study drug (ocrelizumab) for all participants and frequent MRI scans throughout the study. Blood and stool biospecimens will be collected, and study participation will last 4 years.
Contact Us
For more information about this study, including how to volunteer, contact:
Katerina Palma
- Phone Number: 1-203-287-6100
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
Newly diagnosed with MS?
Most people with MS start immune suppressing medications immediately after their diagnosis and remain on these medications indefinitely. However, emerging data suggests that at least some patients may not require lifelong immune suppression to control their MS.
The AMS05 clinical trial is testing the highly effective MS medication, ocrelizumab, in people with early relapsing MS, to see if a short-term treatment can lead to lasting remission. The study will provide study drug (ocrelizumab) for all participants and frequent MRI scans throughout the study. Blood and stool biospecimens will be collected, and study participation will last 4 years.
Eligibility Criteria
Are you eligible?
- Age 18-55
- Your first symptoms of MS were within the last 2 years
- Not yet started a treatment for your MS
- Not currently pregnant or planning pregnancy within the next 4 years
